• Je něco špatně v tomto záznamu ?

Long-term treatment with selective PI3Kδ inhibitor leniolisib in adults with activated PI3Kδ syndrome

VK. Rao, E. Kulm, J. Grossman, D. Buchbinder, H. Chong, J. Bradt, S. Webster, A. Šedivá, VA. Dalm, G. Uzel

. 2024 ; 8 (12) : 3092-3108. [pub] 20240625

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013452

Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) is an inborn error of immunity that manifests as immune deficiency and dysregulation; symptoms include frequent infections and lymphoproliferation. In our dose-finding and phase 3 placebo-controlled trials, treatment with the selective PI3Kδ inhibitor leniolisib reduced lymphoproliferation and normalized lymphocyte subsets. Here, we present 6 years of follow-up from the 6 adult patients in the original dose-finding trial receiving leniolisib. We used data from the ongoing open-label extension study, which was supplemented at later time points by investigators, including health-related quality of life (HRQoL) assessed through a clinician-reported questionnaire. We observed improvements in HRQoL: 5 of 6 patients experienced an increase in physical capabilities and socialization, and a decrease in prescribed medications. Immune subsets improved in all patients: mean transitional B-cell levels decreased from 38.17% to 2.47% and the CD4:CD8 T-cell ratio normalized to 1.11. Manifestations seen before and within the first year of leniolisib exposure, such as infections and gastrointestinal conditions, attenuated after year 2, with few new conditions emerging out to year 6. Thrombocytopenia or lymphopenia remained present in half of patients at year 6. Of 83 adverse events through year 5, 90.36% were grade 1; none were grade 4/5 nor deemed leniolisib related. Collectively, we saw an enhancement in HRQoL as well as durable changes in lymphocyte subsets and clinical manifestations, further supporting the use of leniolisib as a long-term therapeutic option for the treatment of APDS. This trial was registered at www.ClinicalTrials.gov as #NCT02859727.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013452
003      
CZ-PrNML
005      
20240905134336.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/bloodadvances.2023011000 $2 doi
035    __
$a (PubMed)38593221
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rao, V Koneti $u National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD $1 https://orcid.org/0000000278816902
245    10
$a Long-term treatment with selective PI3Kδ inhibitor leniolisib in adults with activated PI3Kδ syndrome / $c VK. Rao, E. Kulm, J. Grossman, D. Buchbinder, H. Chong, J. Bradt, S. Webster, A. Šedivá, VA. Dalm, G. Uzel
520    9_
$a Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) is an inborn error of immunity that manifests as immune deficiency and dysregulation; symptoms include frequent infections and lymphoproliferation. In our dose-finding and phase 3 placebo-controlled trials, treatment with the selective PI3Kδ inhibitor leniolisib reduced lymphoproliferation and normalized lymphocyte subsets. Here, we present 6 years of follow-up from the 6 adult patients in the original dose-finding trial receiving leniolisib. We used data from the ongoing open-label extension study, which was supplemented at later time points by investigators, including health-related quality of life (HRQoL) assessed through a clinician-reported questionnaire. We observed improvements in HRQoL: 5 of 6 patients experienced an increase in physical capabilities and socialization, and a decrease in prescribed medications. Immune subsets improved in all patients: mean transitional B-cell levels decreased from 38.17% to 2.47% and the CD4:CD8 T-cell ratio normalized to 1.11. Manifestations seen before and within the first year of leniolisib exposure, such as infections and gastrointestinal conditions, attenuated after year 2, with few new conditions emerging out to year 6. Thrombocytopenia or lymphopenia remained present in half of patients at year 6. Of 83 adverse events through year 5, 90.36% were grade 1; none were grade 4/5 nor deemed leniolisib related. Collectively, we saw an enhancement in HRQoL as well as durable changes in lymphocyte subsets and clinical manifestations, further supporting the use of leniolisib as a long-term therapeutic option for the treatment of APDS. This trial was registered at www.ClinicalTrials.gov as #NCT02859727.
650    _2
$a lidé $7 D006801
650    _2
$a dospělí $7 D000328
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a primární imunodeficience $x farmakoterapie $7 D000081207
650    12
$a fosfatidylinositol-3-kinasy třídy I $x antagonisté a inhibitory $7 D058534
650    _2
$a kvalita života $7 D011788
650    _2
$a výsledek terapie $7 D016896
650    _2
$a lidé středního věku $7 D008875
650    _2
$a inhibitory fosfoinositid-3-kinasy $x terapeutické užití $x farmakologie $7 D000081082
650    _2
$a inhibitory proteinkinas $x terapeutické užití $7 D047428
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kulm, Elaine $u Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Bethesda, MD
700    1_
$a Grossman, Jennifer $u Alberta Health Services, Calgary, AB, Canada
700    1_
$a Buchbinder, David $u Division of Hematology, Children's Hospital of Orange County, Orange, CA
700    1_
$a Chong, Hey $u Division of Allergy and Immunology, University of Pittsburgh Medical Center Children's Hospital of Pittsburgh, Pittsburgh, PA
700    1_
$a Bradt, Jason $u Pharming Healthcare Inc, Warren, NJ
700    1_
$a Webster, Sharon $u National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
700    1_
$a Šedivá, Anna $u Department of Immunology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000177302304 $7 xx0000191
700    1_
$a Dalm, Virgil A $u Division of Allergy and Clinical Immunology and Department of Immunology, Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands
700    1_
$a Uzel, Gulbu $u National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
773    0_
$w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 8, č. 12 (2024), s. 3092-3108
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38593221 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134330 $b ABA008
999    __
$a ok $b bmc $g 2143338 $s 1225318
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 8 $c 12 $d 3092-3108 $e 20240625 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

    Možnosti archivace